CY1124948T1 - Συνθεσεις με αντικαρκινικη δραση - Google Patents

Συνθεσεις με αντικαρκινικη δραση

Info

Publication number
CY1124948T1
CY1124948T1 CY20221100089T CY221100089T CY1124948T1 CY 1124948 T1 CY1124948 T1 CY 1124948T1 CY 20221100089 T CY20221100089 T CY 20221100089T CY 221100089 T CY221100089 T CY 221100089T CY 1124948 T1 CY1124948 T1 CY 1124948T1
Authority
CY
Cyprus
Prior art keywords
compositions
compounds
cancer action
cells
formula
Prior art date
Application number
CY20221100089T
Other languages
English (en)
Inventor
Alain Moussy
Abdellah Benjahad
Didier Pez
Franck Sandrinelli
Jason Martin
Willy Picoul
Emmanuel Chevenier
Original Assignee
Ab Science
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ab Science filed Critical Ab Science
Publication of CY1124948T1 publication Critical patent/CY1124948T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

Η παρούσα εφεύρεση αναφέρεται σε ενώσεις του γενικού τύπου (Ι), όπου το Α αντιπροσωπεύει μια προαιρετικά υποκατεστημένη ετεροκυκλική ομάδα, το Β αντιπροσωπεύει μια ομάδα αρυλίου ή ετεροαρυλίου και όπου τα Χ, R1, R2, R3, R4 και R5 είναι όπως ορίζονται στην περιγραφή. Οι ενώσεις του τύπου (Ι) είναι χρήσιμες για την καταστροφή, την αναστολή ή την πρόληψη της ανάπτυξης ή της εξάπλωσης κυττάρων, ιδιαίτερα κακοηθών κυττάρων, στους περιβάλλοντες ιστούς που εμπλέκονται σε μια ποικιλία νόσων ανθρώπων και ζώων.
CY20221100089T 2015-02-05 2022-02-02 Συνθεσεις με αντικαρκινικη δραση CY1124948T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15154028.3A EP3053920B1 (en) 2015-02-05 2015-02-05 Compounds with anti-tumoral activity
PCT/EP2016/052523 WO2016124747A1 (en) 2015-02-05 2016-02-05 Compounds with anti-tumoral activity

Publications (1)

Publication Number Publication Date
CY1124948T1 true CY1124948T1 (el) 2023-01-05

Family

ID=52450012

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20221100089T CY1124948T1 (el) 2015-02-05 2022-02-02 Συνθεσεις με αντικαρκινικη δραση

Country Status (25)

Country Link
US (1) US10570122B2 (el)
EP (2) EP3053920B1 (el)
JP (1) JP6713000B2 (el)
KR (1) KR102544132B1 (el)
CN (1) CN107531685B (el)
AR (1) AR103629A1 (el)
AU (1) AU2016214283B2 (el)
BR (1) BR112017016883B1 (el)
CA (1) CA2975644A1 (el)
CY (1) CY1124948T1 (el)
DK (1) DK3253749T3 (el)
ES (2) ES2796276T3 (el)
HK (1) HK1243700A1 (el)
HR (1) HRP20220114T1 (el)
HU (1) HUE059063T2 (el)
IL (1) IL253779A0 (el)
LT (1) LT3253749T (el)
MX (1) MX2017010157A (el)
PL (1) PL3253749T3 (el)
PT (1) PT3253749T (el)
RS (1) RS62901B1 (el)
RU (1) RU2758259C2 (el)
TW (1) TWI748938B (el)
WO (1) WO2016124747A1 (el)
ZA (1) ZA201705537B (el)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018106643A1 (en) * 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Heterocyclic azoles for the treatment of demyelinating diseases
CN109467531A (zh) * 2017-09-08 2019-03-15 沈阳科创化学品有限公司 一种取代吡啶二羧酸衍生物的制备方法
CN112225733B (zh) * 2020-11-25 2022-12-09 湖南科技大学 一种含1,3,4-噻二唑吡啶-2-酮衍生物的制备方法和作为抗癌药物的应用

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US810665A (en) * 1905-10-10 1906-01-23 Joseph Mlada Mold for butter.
US1346834A (en) * 1918-08-17 1920-07-20 Charles E Mcmanus Resilient rod
US3740420A (en) 1967-11-28 1973-06-19 Crown Zellerbach Corp Pharmaceutical compositions with dimethyl sulfoxide
US3743727A (en) 1970-11-16 1973-07-03 Crown Zellerbach Corp Enhancing tissue penetration of certain antimicrobial agents with dimethyl sulfoxide
US4405616A (en) 1975-06-19 1983-09-20 Nelson Research & Development Company Penetration enhancers for transdermal drug delivery of systemic agents
US3989816A (en) 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
CA1163561A (en) 1979-11-06 1984-03-13 Cyril Boroda Preparation containing nitroglycerine and optionally other medicaments and preparation thereof
US4460372A (en) 1981-02-17 1984-07-17 Alza Corporation Percutaneous absorption enhancer dispenser for use in coadministering drug and percutaneous absorption enhancer
US4379454A (en) 1981-02-17 1983-04-12 Alza Corporation Dosage for coadministering drug and percutaneous absorption enhancer
US4411893A (en) 1981-08-14 1983-10-25 Minnesota Mining And Manufacturing Company Topical medicament preparations
CA1236029A (en) 1984-05-14 1988-05-03 Edmund Sandborn Pharmaceutical solutions comprising dimethyl sulfoxide
US4615699A (en) 1985-05-03 1986-10-07 Alza Corporation Transdermal delivery system for delivering nitroglycerin at high transdermal fluxes
DE3815221C2 (de) 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
GB9622363D0 (en) 1996-10-28 1997-01-08 Celltech Therapeutics Ltd Chemical compounds
US5906202A (en) 1996-11-21 1999-05-25 Aradigm Corporation Device and method for directing aerosolized mist to a specific area of the respiratory tract
EP1146875A4 (en) * 1998-12-07 2002-05-02 Smithkline Beecham Corp MYT1 KINASE INHIBITORS
JP4216947B2 (ja) * 1999-05-18 2009-01-28 三井化学株式会社 アミン化合物
ES2294344T3 (es) * 2002-08-02 2008-04-01 Ab Science 2-(3-aminoaril)amino-4-aril-tiazoles y su utilizacion como inhibidores de c-kit.
US8450302B2 (en) * 2002-08-02 2013-05-28 Ab Science 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors
AU2004247013B2 (en) * 2003-05-14 2010-07-08 Neurogenetic Pharmaceuticals, Inc. Compounds and uses thereof in modulating amyloid beta
CN1950347B (zh) * 2003-10-23 2012-04-04 Ab科学公司 作为酪氨酸激酶抑制剂的2-氨基芳基噁唑化合物
WO2006010637A2 (en) 2004-07-30 2006-02-02 Gpc Biotech Ag Pyridinylamines
JP2008510766A (ja) 2004-08-27 2008-04-10 ゲーペーツェー ビオテック アーゲー ピリミジン誘導体
US20080242704A1 (en) * 2005-04-04 2008-10-02 Ab Science Substituted Oxazole Derivatives and their Use as Tyrosine Kinase Inhibitors
UA92746C2 (en) * 2005-05-09 2010-12-10 Акилайон Фармасьютикалз, Инк. Thiazole compounds and methods of use
JP5214096B2 (ja) * 2005-06-17 2013-06-19 富士フイルムファインケミカルズ株式会社 新規なビピリジン誘導体
EP1904065A2 (en) * 2005-07-14 2008-04-02 AB Science Use of dual c-kit/fgfr3 inhibitors for treating multiple myeloma
EA015034B1 (ru) * 2005-09-13 2011-04-29 Янссен Фармацевтика Н.В. 2-анилин-4-арилзамещенные тиазольные производные
GB0524436D0 (en) * 2005-11-30 2006-01-11 Novartis Ag Organic compounds
CA2647819C (en) * 2006-03-31 2012-12-11 Novartis Ag Phenylcyclohexyl derivatives as dgat1 inhibitors
JO3019B1 (ar) * 2006-04-19 2016-09-05 Janssen Pharmaceutica Nv ثلاثي مستبدل 4،2،1-ثلاثي زولات
WO2007131953A1 (en) 2006-05-12 2007-11-22 Ab Science A new process for the synthesis of 2-aminoxazole compounds
FR2901273B1 (fr) * 2006-05-19 2010-12-24 Anaconda Pharma Inhibiteurs du virus du papillome humain et les compositions pharmaceutiques les contenant
MX2009007302A (es) * 2007-01-23 2009-07-15 Palau Pharma Sa Derivados de purina.
AU2008218950A1 (en) * 2007-02-22 2008-08-28 Irm Llc Thiazole derivatives as modulators of G protein-coupled receptors
GB0709031D0 (en) * 2007-05-10 2007-06-20 Sareum Ltd Pharmaceutical compounds
US8420695B2 (en) * 2008-07-09 2013-04-16 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
JP2012180281A (ja) * 2009-06-29 2012-09-20 Dainippon Sumitomo Pharma Co Ltd 新規オキサジアゾール誘導体
EP2454239B1 (en) * 2009-07-15 2014-08-13 Janssen Pharmaceuticals Inc. Substituted triazole and imidazole derivatives as gamma secretase modulators
EP2499282B1 (en) * 2009-11-09 2015-04-22 NeuroGenetic Pharmaceuticals, Inc. Gamma-secretase modulatory compounds, methods for identifying same, and uses therefor
AR079993A1 (es) * 2010-01-12 2012-03-07 Ab Science Derivados de azol, composiciones farmaceuticas y sus usos para tratar trastornos mediados por una sobreactividad de quinasas
GB201012105D0 (en) 2010-07-19 2010-09-01 Domainex Ltd Novel pyrimidine compounds
EP2616443A1 (en) * 2010-09-14 2013-07-24 Exelixis, Inc. Phtalazine derivatives as jak1 inhibitors
WO2012068210A1 (en) * 2010-11-18 2012-05-24 Janssen Pharmaceutica Nv Pyridyl-thiazolyl inhibitors of pro-matrix metalloproteinase activation
WO2012162461A1 (en) * 2011-05-25 2012-11-29 Janssen Pharmaceutica Nv Phenyl-thiazolyl inhibitors of pro-matrix metalloproteinase activation
US8551992B2 (en) * 2011-05-27 2013-10-08 Neosome Life Sciences, LLC Aminooxazole inhibitors of cyclin dependent kinases
MX2014001079A (es) * 2011-07-27 2014-09-12 Ab Science Derivados de oxazoly tiazol como inhibidores de la proteina quinasa selectiva (c-kit).
KR101896035B1 (ko) * 2011-08-23 2018-09-07 덕산네오룩스 주식회사 유기전기소자용 신규 화합물, 이를 이용하는 유기전기소자 및 그 단말
CN103436048B (zh) * 2013-08-08 2014-12-03 陕西师范大学 硫脲供体双桥链有机染料及其应用
US20150045353A1 (en) * 2013-08-09 2015-02-12 Neurogenetic Pharmaceuticals, Inc. Formulations containing gamma secretase modulators, methods for preparation and delivery thereof
CN106414433A (zh) * 2014-03-24 2017-02-15 Ab科学有限公司 作为脾酪氨酸激酶抑制剂的二氮杂螺烷酮取代的噁唑衍生物
EP3144307A1 (en) * 2015-09-18 2017-03-22 AB Science Novel oxazole derivatives that inhibit syk

Also Published As

Publication number Publication date
RU2758259C2 (ru) 2021-10-27
ES2796276T3 (es) 2020-11-26
RU2017127484A (ru) 2019-03-05
WO2016124747A1 (en) 2016-08-11
HUE059063T2 (hu) 2022-10-28
KR20170117407A (ko) 2017-10-23
LT3253749T (lt) 2022-02-25
DK3253749T3 (da) 2022-02-28
CA2975644A1 (en) 2016-08-11
RU2017127484A3 (el) 2019-08-14
US10570122B2 (en) 2020-02-25
PT3253749T (pt) 2022-02-03
ES2905412T3 (es) 2022-04-08
TWI748938B (zh) 2021-12-11
HK1243700A1 (zh) 2018-07-20
JP6713000B2 (ja) 2020-06-24
TW201636345A (zh) 2016-10-16
HRP20220114T1 (hr) 2022-04-15
IL253779A0 (en) 2017-09-28
AU2016214283B2 (en) 2020-07-16
RS62901B1 (sr) 2022-03-31
JP2018504415A (ja) 2018-02-15
PL3253749T3 (pl) 2022-03-07
EP3253749A1 (en) 2017-12-13
BR112017016883A2 (pt) 2018-03-27
EP3053920B1 (en) 2020-04-08
AU2016214283A1 (en) 2017-08-10
CN107531685A (zh) 2018-01-02
CN107531685B (zh) 2021-04-23
MX2017010157A (es) 2017-12-18
AR103629A1 (es) 2017-05-24
BR112017016883B1 (pt) 2023-03-07
ZA201705537B (en) 2020-11-25
EP3053920A1 (en) 2016-08-10
KR102544132B1 (ko) 2023-06-15
EP3253749B1 (en) 2021-12-08
US20180079747A1 (en) 2018-03-22

Similar Documents

Publication Publication Date Title
CY1124187T1 (el) Ετεροκυκλικα αμιδια ως αναστολεις κινασης
CY1122821T1 (el) Παραγωγα 1,3-βενζοδιοξολιου ως αναστολεις εζη1 ή/και εζη2
CY1121804T1 (el) Καινοτομες ενωσεις πυριμιδινης και πυριδινης και η χρηση τους
CY1124478T1 (el) Ετεροκυκλικες ενωσεις ως αναστολεις της κiνασης ret
CY1121706T1 (el) Ενωσεις υποκατασταθεισες διυδροϊσοκινολινονης
CY1122065T1 (el) Ενωσεις αλκυλ-αμιδο-υποκατεστημενου πυριδυλιου χρησιμες ως διαμορφωτες των αποκρισεων il-12, il-23 και/η ιfναλφα
CY1124537T1 (el) Παραγωγο πυριδονης που εχει τετραϋδροπυρανυλ μεθυλ ομαδα
CY1124592T1 (el) Ζιζανιοκτονως δραστικα 3-φαινυλοïσοξαζολινο-5-καρβοξαμιδια αποτελουμενα απο τετραϋδρο- και διυδροφουρανοκαρβοξυλικα οξεα και εστερες
CY1124638T1 (el) Ενωσεις κυκλικων δινουκλεοτιδιων
CY1124948T1 (el) Συνθεσεις με αντικαρκινικη δραση
CY1124206T1 (el) Αναστολεις πυριδοπυριμδινονης cdk2/4/6
CY1124222T1 (el) Ενωσεις πυριδινονης-πυριδινυλιου υποκατεστημενες με μεθυλο/φθορο-πυριδινυλο-μεθοξυ και ενωσεις πυριδινονης-πυριδινυλιου υποκατεστημενες με φθορο-πυριδινυλο-μεθοξυ
CY1121188T1 (el) Αμιδο-υποκατεστημενες ετεροκυκλικες ενωσεις χρησιμες ως διαμορφωτες των αποκρισεων il-12, il-23 και/η ifn-αλφα
CY1124959T1 (el) Αναστολεις λυσινης ειδικης απομεθυλασης-1
CY1123237T1 (el) Αρυλο και ετεροαρυλο συμπυκνωμενες λακταμες
UY36999A (es) Derivados de aryl oxadiazol fungicidas
CY1124173T1 (el) Υποκατεστημενες ενωσεις αμινοπουρινης, συνθεσεις αυτων και μεθοδοι θεραπειας με αυτες
CY1120834T1 (el) Δικυκλικες αζωτουχες ενωσεις ως αγωνιστες μουσκαρινικων υποδοχεων μ1
UY37062A (es) Derivados de aryl oxadiazol fungicidas
CY1119134T1 (el) Υποδοχεις της νεπριλυσινης
CR20160241A (es) Nuevas dihidroquinolizinonas para el tratamiento y profilaxis de la infección por virus de la hepatitis b
CY1123988T1 (el) Ενωση πυριδινης
CY1122945T1 (el) Αναλογα διοξολανιου της ουριδινη για τη θεραπεια του καρκινου
CY1116405T1 (el) Ν1/ν2-λακταμικοι αναστολεις ακετυλο-coa καρβοξυλασης
CL2018003381A1 (es) Derivados de tiazol microbiocidas.